197 related articles for article (PubMed ID: 26142330)
1. Growth differentiation factor-15 in children and adolescents with thalassemia intermedia: Relation to subclinical atherosclerosis and pulmonary vasculopathy.
Tantawy AA; Adly AA; Ismail EA; Youssef OI; Ali ME
Blood Cells Mol Dis; 2015 Aug; 55(2):144-50. PubMed ID: 26142330
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
[TBL] [Abstract][Full Text] [Related]
3. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia.
Musallam KM; Taher AT; Duca L; Cesaretti C; Halawi R; Cappellini MD
Blood Cells Mol Dis; 2011 Dec; 47(4):232-4. PubMed ID: 21865063
[TBL] [Abstract][Full Text] [Related]
4. Soluble fms-Like Tyrosine Kinase 1 as a Link Between Angiogenesis and Endothelial Dysfunction in Pediatric Patients With β-Thalassemia Intermedia.
Tantawy AAG; Adly AAM; Ismail EAR; Youssef OI; Ali ME
Clin Appl Thromb Hemost; 2017 Nov; 23(8):943-950. PubMed ID: 28301910
[TBL] [Abstract][Full Text] [Related]
5. The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/β
Larissi K; Politou M; Margeli A; Poziopoulos C; Flevari P; Terpos E; Papassotiriou I; Voskaridou E
Blood Cells Mol Dis; 2019 Jul; 77():137-141. PubMed ID: 31071550
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children.
Ragab SM; Safan MA; Obeid OM; Sherief AS
Hematology; 2015 May; 20(4):228-38. PubMed ID: 25056687
[TBL] [Abstract][Full Text] [Related]
7. Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.
Sherief LM; Dawood O; Ali A; Sherbiny HS; Kamal NM; Elshanshory M; Alazez OA; Alhady MA; Nour M; Mokhtar WA
BMC Pediatr; 2017 Mar; 17(1):69. PubMed ID: 28279156
[TBL] [Abstract][Full Text] [Related]
8. Increased serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients on maintenance hemodialysis.
Yilmaz H; Çelik HT; Gurel OM; Bilgic MA; Namuslu M; Bozkurt H; Ayyildiz A; Inan O; Bavbek N; Akcay A
Herz; 2015 May; 40 Suppl 3():305-12. PubMed ID: 25117302
[TBL] [Abstract][Full Text] [Related]
9. Subclinical atherosclerotic predictive value of inflammatory markers in thalassemia intermedia patients.
Ahmad Ibrahim O; Ahmad AB; Nigm DA; Hussien AN; Mohammad Ibrahim WH
Expert Rev Hematol; 2021 Jul; 14(7):669-677. PubMed ID: 34296962
[TBL] [Abstract][Full Text] [Related]
10. Asymmetric dimethylarginine levels in children with β-thalassemia and their correlations to tricuspid regurgitant jet velocity.
Mohamed el-S; Ibrahim B; Amr D; Noha el-K; Mokhtar M
Pediatr Blood Cancer; 2014 Sep; 61(9):1540-3. PubMed ID: 24753210
[TBL] [Abstract][Full Text] [Related]
11. N-terminal natriuretic peptide and ventilation-perfusion lung scan in sickle cell disease and thalassemia patients with pulmonary hypertension.
Mokhtar GM; Adly AA; El Alfy MS; Tawfik LM; Khairy AT
Hemoglobin; 2010; 34(1):78-94. PubMed ID: 20113292
[TBL] [Abstract][Full Text] [Related]
12. GDF-15 is associated with atherosclerosis in adults with transfusion-dependent beta-thalassemia.
Efat A; Wahb R; Shoeib SAA; Dawod AAE; Abd ElHafez MA; Abd ElMohsen EA; Elkholy A
EJHaem; 2022 May; 3(2):353-361. PubMed ID: 35846052
[TBL] [Abstract][Full Text] [Related]
13. Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
Elbarbary NS; Ismail EA; Roushdy A; Fahmy E
Blood Cells Mol Dis; 2016 Mar; 57():1-7. PubMed ID: 26852648
[TBL] [Abstract][Full Text] [Related]
14. Clinical Predictive Value of Cystatin C in Pediatric Sickle Cell Disease: A Marker of Disease Severity and Subclinical Cardiovascular Dysfunction.
Tantawy AAG; Adly AAM; Ismail EAR; Abdelazeem M
Clin Appl Thromb Hemost; 2017 Nov; 23(8):1010-1017. PubMed ID: 27582023
[TBL] [Abstract][Full Text] [Related]
15. Premature atherosclerosis in non-transfusion-dependent β-thalassemia intermedia.
Hahalis G; Kalogeropoulos A; Terzis G; Tselepis AD; Kourakli A; Mylona P; Grapsas N; Alexopoulos D
Cardiology; 2011; 118(3):159-63. PubMed ID: 21646780
[TBL] [Abstract][Full Text] [Related]
16. Vascular dysfunction in patients with young β-thalassemia: relation to cardiovascular complications and subclinical atherosclerosis.
Adly AA; El-Sherif NH; Ismail EA; El-Zaher YA; Farouk A; El-Refaey AM; Wahba MS
Clin Appl Thromb Hemost; 2015 Nov; 21(8):733-44. PubMed ID: 24989711
[TBL] [Abstract][Full Text] [Related]
17. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia.
Karimi M; Borzouee M; Mehrabani A; Cohan N
Eur J Haematol; 2009 Mar; 82(3):213-8. PubMed ID: 19077048
[TBL] [Abstract][Full Text] [Related]
18. Plasma GDF-15 levels and their association with hormonal and metabolic status in women with polycystic ovary syndrome aged 25-35.
Berberoglu Z; Aktas A; Fidan Y; Canan Yazici A; Aral Y
Minerva Endocrinol; 2014 Jun; 39(2):89-97. PubMed ID: 24736483
[TBL] [Abstract][Full Text] [Related]
19. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis.
Tanrıkulu O; Sarıyıldız MA; Batmaz İ; Yazmalar L; Polat N; Kaplan İ; Çevik R
Acta Reumatol Port; 2017; 42(1):66-72. PubMed ID: 27679935
[TBL] [Abstract][Full Text] [Related]
20. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
